Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Ann Surg Oncol. 2015 May 1;22(12):3809–3815. doi: 10.1245/s10434-015-4572-6

TABLE 1.

Patient, disease, and treatment characteristics (n = 560)

Median age at diagnosis (range) 37 (17–40)
N %
White non-Hispanic
 Yes 483 86.3
 No 77 13.8
Married/living as married
 Yes 430 76.8
 No 130 23.2
Children
 Yes 361 64.5
 No 199 35.5
College education
 Yes 471 84.1
 No 85 15.2
 Unknown 4 0.7
Stage
 1 225 40.2
 2 264 47.1
 3 71 12.7
Tumor size
 T2 and larger 256 45.7
 T1 304 54.3
Nodal involvement
 Any 229 40.9
 None 331 59.1
Estrogen receptor status
 Positive 386 68.9
 Negative 174 31.1
Her-2 neu status
 Positive 172 30.7
 Negative 388 69.3
BRCA 1/2 mutation status
 Positive 61 10.9
 Negative 439 78.4
 Not tested/unknown 60 10.7
First-degree relative with breast or ovarian cancer
 Yes 85 15.2
 No 463 82.7
 Unknown 12 2.1
Anxiety
 Normal (HADS <8) 307 54.8
 Borderline abnormal (HADS 8–10) 123 22.0
 Abnormal (HADS ≥11) 130 23.2
Depression
 Normal (HADS <8) 436 77.9
 Borderline abnormal (HADS 8–10) 83 14.8
 Abnormal (HADS ≥11) 41 7.3
Fear of recurrence
 Very concerned about cancer coming back 186 33.2
 Moderately/a little//not at all concerned 374 66.8

HADS Hospital Anxiety and Depression Scale